GLP-1 drugs linked to vision loss
The gist
The FDA told GLP-1 drugmakers to add a warning label about NAION, a rare eye condition that can cause sudden blindness.
The risk is small, but the warning covers blockbuster weight-loss and diabetes drugs taken by millions.
How it unfolded
- 2024A JAMA Ophthalmology study found diabetes patients prescribed semaglutide were four times as likely to develop NAION as those not prescribed it; the FDA began looking into a possible link.
- Feb 10, 2025An investigatory review in JAMA Ophthalmology reported nine people taking semaglutide and tirzepatide experienced vision issues, including NAION and two other potentially blinding eye conditions.
- Jul 10, 2025The AOA reported about 6% of U.S. adults take GLP-1RAs and that NAION is among the rare ocular side effects that can cause permanent vision loss.
Key terms
- FDA
- A U.S. federal agency that regulates food safety, drugs, vaccines, medical devices, cosmetics and related products.
- GLP-1
- A class of medications that activate the GLP-1 receptor, reducing blood sugar, appetite, and energy intake.
- placebo
- A treatment designed to appear real but having no active pharmaceutical effect, used as a comparison in trials.
Source: Wikipedia